Product Overview
[Drug Name]
Generic Name: Isosorbide Mononitrate Tablets
Trade Name: Xinkang
English Name: Isosorbide Mononitrate Tablets
Chinese Pinyin: Danxiaosuan Yishanlizhi Pian
[Ingredients]
Isosorbide mononitrate. Chemical Name: 1,4:3,6-dianhydro-D-sorbitol-5-mononitrate. Molecular Formula: C6H9NO6. Molecular Weight: 191.14
[Properties]
This product is a white tablet.
[Indications]
Long-term treatment of coronary heart disease; prevention of angina pectoris; treatment of persistent angina pectoris after myocardial infarction; combined with digitalis and/or diuretics for the treatment of chronic congestive heart failure.
[Dosage and Administration]
Oral administration. 0.5-1 tablet at a time, 2-3 times daily. In severe cases, 2 tablets may be used, 2-3 times daily.
[Adverse Reactions]
Nitrates may cause vasodilatory headaches initially, which usually resolve after several days of continuous use. Facial flushing, dizziness, orthostatic hypotension, and reflex tachycardia may also occur. Rarely, significant hypotension, bradycardia, exacerbated angina, and syncope may occur.
[Contraindications]
1. Acute circulatory failure (shock, circulatory collapse); 2. Severe hypotension (systolic blood pressure ≥ 3. Acute myocardial infarction with low filling pressures (unless under continuous hemodynamic monitoring); 4. Hypertrophic obstructive cardiomyopathy; 5. Constrictive pericarditis or cardiac tamponade; 6. Severe anemia; 7. Glaucoma; 8. Increased intracranial pressure; 9. Patients allergic to nitro compounds.
[Precautions]
Patients with acute myocardial infarction and low filling pressure should avoid systolic blood pressure below 90 mmHg. Use with caution in patients with aortic and/or mitral stenosis, postural hypotension, and renal insufficiency.
[Use in Special Populations]
Precautions for use in children:
Studies of this class of drugs have been conducted in adults. Comparative data on use in children and adults are not available. Therefore, use in children is not recommended.
Precautions for pregnancy and lactation:
No embryotoxic effects have been observed in animal studies, and the risk of IS is unknown. Whether MN is excreted in breast milk is unknown, but due to a lack of experience with its use in pregnant and lactating women, caution is advised.
Precautions for Elderly Patients:
Elderly patients may be more sensitive to this class of drugs and may be more susceptible to reactions such as dizziness.
[Drug Interactions]
Combination use with other vasodilators, calcium antagonists, beta-blockers, antihypertensives, tricyclic antidepressants, and alcohol may potentiate the blood pressure-lowering effect of this class of drugs.
[Pharmacological Actions]
Isosorbide mononitrate (ISMN) is the primary biologically active ingredient of isosorbide dinitrate. ISMN is a metabolite, and like other organic nitrates, its main pharmacological effect is to relax vascular smooth muscle. ISMN releases nitric oxide (NO), which is the same as endothelial relaxing factor, activating guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby relaxing vascular smooth muscle, dilating peripheral arteries and veins, and having a stronger dilating effect on veins. Venous dilation causes blood to remain in the periphery, reducing the amount of blood returning to the heart, and reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arterial dilation increases peripheral vascular resistance, Systolic arterial pressure and mean arterial pressure (afterload) decrease. Coronary artery dilation increases coronary perfusion. The overall effect is reduced myocardial oxygen consumption, increased oxygen supply, and relief of angina pectoris. Carcinogenic and mutagenic effects have not been observed in animal studies.
[Storage]
Store in a sealed container away from light.
[Specification]
20 mg
[Packaging]
Aluminum-plastic packaging. 48 tablets/box.
[Expiry Date]
24 months.
[Approval Number]
National Medicine Standard H10940039
[Manufacturer]
Company Name: Lunan Beite Pharmaceutical Co., Ltd.
